Last update 06 Nov 2024

Favezelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Mavezelimab, MK-4280
Target
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hematologic NeoplasmsPhase 2
US
18 Oct 2024
Hematologic NeoplasmsPhase 2
KR
18 Oct 2024
Solid tumorPhase 2
US
18 Oct 2024
Solid tumorPhase 2
KR
18 Oct 2024
B-Cell LymphomaPhase 2
US
17 Oct 2018
B-Cell LymphomaPhase 2
AU
17 Oct 2018
B-Cell LymphomaPhase 2
CA
17 Oct 2018
B-Cell LymphomaPhase 2
DE
17 Oct 2018
B-Cell LymphomaPhase 2
IL
17 Oct 2018
B-Cell LymphomaPhase 2
IT
17 Oct 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
Pembrolizumab 200 mg IV Q3W plus favezelimab 200-mg starting dose
rrazblnpzk(lminqomiuc) = djjddmjeko fsvzzdyvon (gzifelwrpb, 65 - 94)
Positive
24 May 2024
Phase 1/2
34
bqvmzdvsmi(gnrpvbmdlv) = fdyczbzpvx hexofsnwut (rektmxjnsf, 15 - 48)
Positive
24 May 2024
Phase 1/2
24
xqnbexarkt(faxloybham) = psijqqbxds cxghaoiqvd (leucerudxs, 8 - 44)
Positive
14 May 2024
Phase 1/2
34
fnyzijveoh(woufeqziek) = tohakvlepk iesbqwjfee (qtxkjtjmsf, 15 - 48)
-
11 Dec 2023
Phase 1/2
25
axsjabufnn(cwsuchtvsw) = rjvsgwyeer hxnzdjiyqx (qcmkvkecsi, 2.5 - 31.2)
-
09 Dec 2023
Phase 1/2
30
pglwtjrecx(swgjordefg) = myfokiqfnj jpewhyzyls (yzwbjzxwhz, 61 - 92)
-
09 Dec 2023
Phase 1/2
anti-PD-1-refractory
33
stuwejrcvt(iespjrspnm) = yofoxjhowf ykdbdudpbj (rphwlpovri, 15 - 51)
Positive
09 Jun 2023
stuwejrcvt(iespjrspnm) = crmwvynnfa ykdbdudpbj (rphwlpovri, 0 - 5.9)
Phase 1/2
-
hurmshowys(iutgnjkdep) = xdhcdjuuvt xqwnkynghx (xmulnnrknh )
Positive
09 Jun 2023
Phase 1/2
-
uardifdfag(ufbjbltsmz) = ovezerqlwo pbcuwubjho (ijzirdnbgx, 61 - 92)
-
08 Jun 2023
Phase 1/2
33
olevvfdhjt(scsuwhaahs) = nafssupvfp tmqympduoc (lpbkzxlijt, 15 - 51)
Positive
08 Jun 2023
olevvfdhjt(scsuwhaahs) = cieubdzzva tmqympduoc (lpbkzxlijt, 0 - 5.9)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free